Roberta Vilela Lopes Koyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Roberta Vilela Lopes Koyama has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Juarez Antônio Simões Quaresma
Universidade do Estado do Pará
2 shared publications - Ana Beatriz Dias Silva
Universidade do Estado do Pará
1 shared publication Anderson Raiol Rodrigues
Tropical Medicine Group, Federal University of Pará, Av Generalíssimo, 92, Umarizal, Belem, PA, 66055-240, Brazil
1 shared publicationGeorge Alberto da Silva Dias
Center of Biological and Health Sciences, Pará State University, Tv Perebebuí, 2623, Marco, Belem, PA, 66095-662, Brazil
1 shared publication- George Alberto da Silva Dias
Universidade do Estado do Pará
1 shared publication Gilberto Toshimitsu Yoshikawa
Institute of Health Sciences, Federal University of Pará, Av Generalíssimo, 94, Umarizal, Belem, PA, 66050-160, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by Research, Society and Development in Research, Society and Development
- Vol. 14 (4)
O impacto da Artrite Psoriárica na qualidade do sono e nas alterações de humor
Introdução: A artrite psoriásica (APs) é uma doença inflamatória crônica que afeta as articulações e está associada a pacientes portadores de doença psoriásica (DPs) cutânea. A qualidade do sono é frequentemente prejudicada em pacientes com APs, impactando negativamente sua qualidade de vida. Objetivo: Avaliar a qualidade do sono em pacientes diagnosticados com APs e atendidos em um ambulatório de reumatologia da região metropolitana de Belém do Pará. Métodos: É um estudo descritivo e observacional, que incluiu 13 pacientes com diagnóstico confirmado de APs. Utilizou-se um protocolo padronizado para coleta de dados dos prontuários dos pacientes. Resultados e discussão: O perfil epidemiológico corresponde a mulheres, não brancas, entre 61 e 70 anos de idade, procedentes da região metropolitana de Belém. Seus diagnósticos foram atribuídos há mais de 10 anos, apresentam como principal comorbidade associada a Hipertensão Arterial Sistêmica e utilizam secuquinumabe como principal medicação. A manifestação clínica inicial mais prevalente correspondeu a articular ou cutânea com surgimento de lesão secundária após 1 a 5 anos, ocorrendo rigidez matinal superior a 30 minutos e dor entre 5 e 6 na escala visual. Ademais, a sonolência foi pontuada como normal pela escala de sono de Epworth, com boa qualidade do sono no Índice de Qualidade do Sono de Pittsburgh, presença de SAOS pelo Questionário de Berlim e provável depressão e/ou ansiedade na escala de HAD. Conclusões: Os resultados destacam a influência da APs na qualidade de vida.
- 1 April 2025
- Published by Research, Society and Development in Research, Society and Development
- Vol. 14 (4)
Open AccessO impacto da Artrite Psoriárica na qualidade do sono e nas alterações de humor
Introdução: A artrite psoriásica (APs) é uma doença inflamatória crônica que afeta as articulações e está associada a pacientes portadores de doença psoriásica (DPs) cutânea. A qualidade do sono é frequentemente prejudicada em pacientes com APs, impactando negativamente sua qualidade de vida. Objetivo: Avaliar a qualidade do sono em pacientes diagnosticados com APs e atendidos em um ambulatório de reumatologia da região metropolitana de Belém do Pará. Métodos: É um estudo descritivo e observacional, que incluiu 13 pacientes com diagnóstico confirmado de APs. Utilizou-se um protocolo padronizado para coleta de dados dos prontuários dos pacientes. Resultados e discussão: O perfil epidemiológico corresponde a mulheres, não brancas, entre 61 e 70 anos de idade, procedentes da região metropolitana de Belém. Seus diagnósticos foram atribuídos há mais de 10 anos, apresentam como principal comorbidade associada a Hipertensão Arterial Sistêmica e utilizam secuquinumabe como principal medicação. A manifestação clínica inicial mais prevalente correspondeu a articular ou cutânea com surgimento de lesão secundária após 1 a 5 anos, ocorrendo rigidez matinal superior a 30 minutos e dor entre 5 e 6 na escala visual. Ademais, a sonolência foi pontuada como normal pela escala de sono de Epworth, com boa qualidade do sono no Índice de Qualidade do Sono de Pittsburgh, presença de SAOS pelo Questionário de Berlim e provável depressão e/ou ansiedade na escala de HAD. Conclusões: Os resultados destacam a influência da APs na qualidade de vida.
- 5 October 2018
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 25 (1) , 1-8
Incomplete myelopathy and human T cell lymphotropic virus type-1 (HTLV-1)
This was a cross-sectional prospective study. We performed a multivariate statistical analysis of the neurological signs and symptoms of patients infected with human T cell lymphotropic virus type 1 (HTLV-1) in an attempt to separate them into distinct groups and identify clinical-neurological manifestations that could differentiate the various profiles. The study was performed in the city of Belém (state of Pará), located in the Amazon region of Brazil, from 2014 to 2016. We determined muscle strength and tone, reflexes, sensations, sphincter function, gait, and the Expanded Disability Status Scale score among individuals with HTLV-I. We then used exploratory statistical methods in an attempt to find different profiles and establish distinct groups. We analyzed 60 patients with HTLV-1. The filtering of the data, performed with mixed PCA, gave rise to a streamlined database with the most informative data and suggested the formation of three statistically distinct groups: asymptomatic carriers (AC), mono/oligosymptomatic (MOS), and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSPd), AC and MOS (p = 0.002), AC and HAM/TSPd (p < 0.001), and HAM/TSPd and MOS (p = 0.001). The subsequent cluster analysis confirmed the formation of three clusters. The classification and regression tree demonstrated that altered gait was the most important variable for the classification of an individual with HAM/TSPd and that, in the absence of this impairment, hyperreflexia characterized MOS. The present study was able to separate patients infected by HTLV-1 into three clinical groups (AC, HAM/TSPd, and MOS) and identify clinical manifestations that could differentiate the various patient groups.
- 5 October 2018
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 25 (1) , 1-8
Incomplete myelopathy and human T cell lymphotropic virus type-1 (HTLV-1)
This was a cross-sectional prospective study. We performed a multivariate statistical analysis of the neurological signs and symptoms of patients infected with human T cell lymphotropic virus type 1 (HTLV-1) in an attempt to separate them into distinct groups and identify clinical-neurological manifestations that could differentiate the various profiles. The study was performed in the city of Belém (state of Pará), located in the Amazon region of Brazil, from 2014 to 2016. We determined muscle strength and tone, reflexes, sensations, sphincter function, gait, and the Expanded Disability Status Scale score among individuals with HTLV-I. We then used exploratory statistical methods in an attempt to find different profiles and establish distinct groups. We analyzed 60 patients with HTLV-1. The filtering of the data, performed with mixed PCA, gave rise to a streamlined database with the most informative data and suggested the formation of three statistically distinct groups: asymptomatic carriers (AC), mono/oligosymptomatic (MOS), and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSPd), AC and MOS (p = 0.002), AC and HAM/TSPd (p < 0.001), and HAM/TSPd and MOS (p = 0.001). The subsequent cluster analysis confirmed the formation of three clusters. The classification and regression tree demonstrated that altered gait was the most important variable for the classification of an individual with HAM/TSPd and that, in the absence of this impairment, hyperreflexia characterized MOS. The present study was able to separate patients infected by HTLV-1 into three clinical groups (AC, HAM/TSPd, and MOS) and identify clinical manifestations that could differentiate the various patient groups.
- Open Access
HTLV-1, Immune Response and Autoimmunity
Human T-lymphotropic virus type-1 (HTLV-1) infection is associated with adult T-cell leukemia/lymphoma (ATL). Tropical spastic paraparesis/HTLV-1-associated myelopathy (PET/HAM) is involved in the development of autoimmune diseases including Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Sjögren’s Syndrome (SS). The development of HTLV-1-driven autoimmunity is hypothesized to rely on molecular mimicry, because virus-like particles can trigger an inflammatory response. However, HTLV-1 modifies the behavior of CD4+ T cells on infection and alters their cytokine production. A previous study showed that in patients infected with HTLV-1, the activity of regulatory CD4+ T cells and their consequent expression of inflammatory and anti-inflammatory cytokines are altered. In this review, we discuss the mechanisms underlying changes in cytokine release leading to the loss of tolerance and development of autoimmunity.
Open AccessHTLV-1, Immune Response and Autoimmunity
Human T-lymphotropic virus type-1 (HTLV-1) infection is associated with adult T-cell leukemia/lymphoma (ATL). Tropical spastic paraparesis/HTLV-1-associated myelopathy (PET/HAM) is involved in the development of autoimmune diseases including Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Sjögren’s Syndrome (SS). The development of HTLV-1-driven autoimmunity is hypothesized to rely on molecular mimicry, because virus-like particles can trigger an inflammatory response. However, HTLV-1 modifies the behavior of CD4+ T cells on infection and alters their cytokine production. A previous study showed that in patients infected with HTLV-1, the activity of regulatory CD4+ T cells and their consequent expression of inflammatory and anti-inflammatory cytokines are altered. In this review, we discuss the mechanisms underlying changes in cytokine release leading to the loss of tolerance and development of autoimmunity.